Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 -0.61%50 EBITDA Margin % is 3.71% as of May. 2026, which is 5% above its 10-year median of 3.55. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.07 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Pharmarise Holdings ranks worse than 67.47% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharmarise Holdings EBITDA Margin % Related Terms
Pharmarise Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings (TSE:2796) has a EBITDA Margin % of 3.71% as of May. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmarise Holdings and its competitors. This is near median its historical median of 3.55. Over the past decade, Pharmarise Holdings' EBITDA Margin % has ranged from 2.53 to 5.22. According to the industry distribution chart, Pharmarise Holdings ranks #448 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 67.5%.
Is Pharmarise Holdings' EBITDA Margin % too high?
Pharmarise Holdings' current EBITDA Margin % of 3.71% is near median its 10-year median of 3.55. Over the past 10 years, this metric has ranged from a low of 2.53 to a high of 5.22. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Pharmarise Holdings' value of 3.71% is 63.7% below this industry median. Based on the distribution chart, Pharmarise Holdings ranks #448 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #448 out of 664 companies for EBITDA Margin %. This places Pharmarise Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Pharmarise Holdings' value of 3.71% is 63.7% below this benchmark. Historically, Pharmarise Holdings' own EBITDA Margin % has ranged from 2.53 to 5.22 over the past decade. While the company's 10-year median is 3.55 vs. the industry median of 10.21, Pharmarise Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmarise Holdings's current EBITDA Margin % of 3.71% is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current EBITDA Margin % is 3.71%, which is near median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.07, compared to a current price of 円491.00 — trading 19.3% below its estimated fair value. The current EBITDA Margin % is 3.71%, which is near median its 10-year median of 3.55 and 63.7% below the Healthcare Providers & Services industry median of 10.21. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current EBITDA Margin % is 3.71% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.3% below its estimated GF Value™ of 円608.07.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
EBITDA Margin %: 3.71% (near median its 10-year median of 3.55)
GF Value™: 円608.07 vs. price of 円491.00 (19.3% below fair value)
Industry Position: 63.7% below the Healthcare Providers & Services median (#448 of 664)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
